Enzyme Or Coenzyme Containing Patents (Class 424/94.1)
  • Patent number: 10717990
    Abstract: A method of altering a eukaryotic cell is provided including transfecting the eukaryotic cell with a nucleic acid encoding RNA complementary to genomic DNA of the eukaryotic cell, transfecting the eukaryotic cell with a nucleic acid encoding an enzyme that interacts with the RNA and cleaves the genomic DNA in a site specific manner, wherein the cell expresses the RNA and the enzyme, the RNA binds to complementary genomic DNA and the enzyme cleaves the genomic DNA in a site specific manner.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: July 21, 2020
    Assignee: President and Fellows of Harvard College
    Inventors: Prashant G. Mali, George M. Church, Luhan Yang
  • Patent number: 10711259
    Abstract: Compositions comprising polypeptides having xylanase activity and polypeptides having arabinofuranosidase activity for use in e.g. animal feed. Polypeptides having arabinofuranosidase activity, polypeptides having xylanase activity and polynucleotides encoding the polypeptides. Nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptide.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 14, 2020
    Assignee: Novozymes A/S
    Inventors: Wei Peng, Ninfa Rangel Pedersen, Dan Pettersson, Jens Magnus Ekloff, Soren Nymand-Grarup, Lorena G. Palmen, Rune Nygaard Monrad, Nikolaj Spodsberg, Mary Ann Stringer, Charlotte Blom, Lars Kiemer, Kristian Bertel Romer M. Krogh, Jesper Salomon
  • Patent number: 10704098
    Abstract: Compositions and methods for the treatment and diagnosis of eosinophilic esophagitis disclosed.
    Type: Grant
    Filed: October 29, 2015
    Date of Patent: July 7, 2020
    Assignee: The Children's Hospital of Philadelphia
    Inventors: Hakon Hakonarson, Patrick Sleiman
  • Patent number: 10695320
    Abstract: The invention provides compositions comprising a medium chain triglyceride and a urolithin. The invention also provides uses and methods associated with, or making use of the compositions, such as a medicament, dietary supplement, functional food or medical food and in the treatment and/or prophylaxis of a muscle-related pathological condition.
    Type: Grant
    Filed: August 26, 2016
    Date of Patent: June 30, 2020
    Assignee: Amazentis SA
    Inventors: Penelope Andreux, Christopher Rinsch, William Blanco-Bose
  • Patent number: 10655123
    Abstract: The invention provides a method of modifying a targeted site of a double stranded DNA, including a step of contacting a complex wherein a nucleic acid sequence-recognizing module that specifically binds to a target nucleotide sequence in a selected double stranded DNA and a nucleic acid base converting enzyme are linked, with the double stranded DNA, to convert one or more nucleotides in the targeted site to other one or more nucleotides or delete one or more nucleotides, or insert one or more nucleotides into the targeted site, without cleaving at least one strand of the double stranded DNA in the targeted site.
    Type: Grant
    Filed: March 4, 2015
    Date of Patent: May 19, 2020
    Assignee: National University Corporation Kobe University
    Inventors: Keiji Nishida, Akihiko Kondo, Satomi Kojima
  • Patent number: 10568843
    Abstract: The present invention provides a method of preparing highly stable microcapsule powders or microparticles containing a fat-soluble nutrient having multiple double bonds.
    Type: Grant
    Filed: October 12, 2015
    Date of Patent: February 25, 2020
    Assignee: Zhejiang Medicine Co., Ltd
    Inventors: Xinde Xu, Di Zhou, Lihua Zhang, Bin Shao
  • Patent number: 10568866
    Abstract: A composition of natural and chemical nutrients such as Vitamin C, Vitamin B-complex, Vitamin E, Aronia melanocarpa extract, Fucoidan, Ginger extract, Zinc, Selenium, Alpha lipoic acid, White mulberry extract, Lychee fruit extract and Sour (Tart) cherry fruit extract are made for mammal consumption in liquid or solid form. This specific composition is used for increasing innate immunity in the mammal before and after the infection has occurred.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: February 25, 2020
    Inventor: Matthias W Rath
  • Patent number: 10519504
    Abstract: Methods and formulations for treating oncological disorders in humans using epimetabolic shifters, multidimensional intracellular molecules or environmental influencers are described.
    Type: Grant
    Filed: May 11, 2010
    Date of Patent: December 31, 2019
    Assignee: Berg LLC
    Inventors: Niven Rajin Narain, John Patrick McCook, Rangaprasad Sarangarajan
  • Patent number: 10519324
    Abstract: Materials and methods for prevention of biofouling are described that incorporate the presence of a conotoxin peptide on a surface. The conotoxin peptide is either directly or indirectly adhered to the surface and interferes with the ability of biofouling organisms to settle on the surface.
    Type: Grant
    Filed: May 19, 2016
    Date of Patent: December 31, 2019
    Assignee: Clemson University Research Foundation
    Inventors: Andrew S. Mount, Bin San Chan, Mary Beth Johnstone
  • Patent number: 10501557
    Abstract: An Fc-binding polypeptide of improved alkali stability, comprising a mutant of an Fc-binding domain of Staphylococcus Protein A (SpA), as defined by SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO:3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:22, SEQ ID NO 51 or SEQ ID NO 52 wherein at least the asparagine or serine residue at the position corresponding to position 11 in SEQ ID NO:4-7 has been mutated to an amino acid selected from the group consisting of glutamic acid, lysine, tyrosine, threonine, phenylalanine, leucine, isoleucine, tryptophan, methionine, valine, alanine, histidine and arginine.
    Type: Grant
    Filed: November 16, 2015
    Date of Patent: December 10, 2019
    Assignee: GE HEALTHCARE BIOPROCESS R&D AB
    Inventors: Gustav Rodrigo, Tomas Bjorkman, Mats Ander
  • Patent number: 10494417
    Abstract: In one aspect, the invention relates to peptides comprising the Bcr-Abl coiled-coil oligomerization domain and an alpha helix stabilizing moiety, mutant forms thereof, truncated forms thereof, derivatives thereof, and related peptides, which are useful as inhibitors of the Bcr-Abl chimeric protein; pharmaceutical compositions comprising the compounds; and methods of treating hyperproliferative disorders associated with Bcr-Abl using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 25, 2015
    Date of Patent: December 3, 2019
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Carol Lim, Benjamin J. Bruno, Geoffrey D. Miller, Andrew S. Dixon
  • Patent number: 10485836
    Abstract: A composition and its use in anti-fatigue are provided, wherein the composition comprises a first component being a Cistanche tubulosa extract and a second component being ubiquinone (Q10) and/or ubiquinol (QH), and the weight ratio of the first component to the second component ranges from 0.67:1 to 10:1. The composition is used for anti-fatigue and is a pharmaceutical composition, a food composition, a cosmetic composition, a care product composition, or a feed composition. The pharmaceutical composition is used for treating or preventing chronic fatigue syndrome, and the food composition, the cosmetic composition, the care product composition and the feed composition are used for at least one of increasing endurance performance, increasing athletic ability, increasing physical strength, recovering physical strength, promoting fatigue elimination, preventing myocardial weakness, helping ameliorate myocardial weakness and helping improve cardiac function.
    Type: Grant
    Filed: February 13, 2018
    Date of Patent: November 26, 2019
    Assignee: SINPHAR PHARMACEUTICAL CO., LTD.
    Inventors: Wen-Pang Huang, Ya-Ting Wu
  • Patent number: 10478447
    Abstract: The disclosure provides an oral antiviral supplement composition comprising a lysine, an ascorbic compound, a flavonoid glycoside, a threonine, and a pyridoxine. The disclosure also provides a method of reducing viral replication in a cell comprising treating a virus-infected cell with a composition of the disclosure. The disclosure further provides a method for the treatment and prophylaxis of a viral infection in a patient comprising administering a composition of the disclosure.
    Type: Grant
    Filed: January 29, 2018
    Date of Patent: November 19, 2019
    Assignee: Vymedic, LLC
    Inventors: Kenneth E. Phillips, Cynthia A. Winning
  • Patent number: 10413563
    Abstract: A novel process for improving neurochemical health includes a multi-day treatment program including intravenous delivery of nicotinamide adenine dinucleotide (NAD) to at least partially restore a patient's brain to a desired chemical balance. Intravenous delivery of NAD is synergistically combined with delivery of selected amino acids and, depending on the ailment being treated, a combination of ozone, testosterone, glutathione, Myers cocktail or other specified compounds.
    Type: Grant
    Filed: May 9, 2018
    Date of Patent: September 17, 2019
    Assignee: Emerald Neuro-Recover, LLC
    Inventor: Joseph W. Pappas
  • Patent number: 10406104
    Abstract: The present application relates to a method for the preparation of a nanosuspension comprising nanoparticles of at least one natural material and an extract of at least one natural material, wherein the method comprises the steps of providing particles of at least one natural material having a particle size (D100) of less than 320 ?m; providing an extract of at least one natural material; dispersing said particles of at least one natural material and said extract of at least one natural material in a solvent; and milling the dispersion to a particle size (D90) of below 1000 nm (D90<1000 nm). Furthermore, the present application also relates to a nanosuspension prepared according to said method, and the use of such nanosuspension for the preparation of a medicament and/or nutritional supplement.
    Type: Grant
    Filed: August 4, 2016
    Date of Patent: September 10, 2019
    Assignee: Apurano Life Sciences GmbH
    Inventor: Werner Brand
  • Patent number: 10357547
    Abstract: The invention relates to the field of medicine, specifically to the field of treatment of dermatitis or eczema, even more specifically to the field of treatment of atopic dermatitis. The invention relates to a novel composition and a novel kit of parts, both comprising an anti-inflammatory compound and a compound specifically targeting a bacterial cell, preferably a gram positive bacterial cell. The invention further relates to said composition and/or kit of parts for medical use, preferably for treating an individual suffering from eczema.
    Type: Grant
    Filed: July 10, 2014
    Date of Patent: July 23, 2019
    Assignee: Micreos Human Health B.V.
    Inventors: Mark Leonard Offerhaus, Fritz Eichenseher, Martin Johannes Loessner
  • Patent number: 10328090
    Abstract: Described herein are formulations and methods for treating, managing, or preventing sleeplessness or restlessness, for increasing focus or concentration, or for decreasing anxiety. The formulations comprise honokiol and magnolol, which are present in magnolia bark extract, in admixture with one or more polyunsaturated fatty acids, such as those found in virgin salmon oil. As compared to other lipid formulations of honokiol and magnolol, the formulations show improved stability and increased uptake.
    Type: Grant
    Filed: January 18, 2016
    Date of Patent: June 25, 2019
    Assignee: ST IP Holding AG
    Inventor: Bomi P. Framroze
  • Patent number: 10328152
    Abstract: A method of treatment is disclosed, comprising administering a composition of Cyclodextrin and reduced, nanonized L-Glutathione to a patient in need of treatment, wherein the L-Glutathione molecule is non-acetylated, non-Esterified, and non-fatty acid attached.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: June 25, 2019
    Inventors: Nayan Patel, Chinh Tran
  • Patent number: 10322170
    Abstract: The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.
    Type: Grant
    Filed: March 24, 2016
    Date of Patent: June 18, 2019
    Assignees: Baxter International Inc., Baxter Healthcare SA
    Inventors: Heinz Gulle, Joris Hoefinghoff, Andreas Goessl, Katarzyna Gorna
  • Patent number: 10278909
    Abstract: The present invention relates to a composition for pharmaceutical, nutritional or cosmetic use, suitable to preserve the physiological condition and health of skin and hair and to reestablish their regenerative functions, characterized in that it comprises a mixture of carnitine, caffeine and arginine as active principle, as such or as derivatives, such as pharmacologically acceptable salts. The effect of preserving the physiologic condition and health of skin and hair, and of reestablishing their regenerative functions is mainly achieved through an increase in ATP production by skin and hair cells.
    Type: Grant
    Filed: June 25, 2015
    Date of Patent: May 7, 2019
    Assignee: Giuliani S.P.A.
    Inventors: Giammaria Giuliani, Anna Benedusi, Barbara Marzani, Antonio Mascolo, Antonio Limitone
  • Patent number: 10284587
    Abstract: The disclosed computer-implemented method for responding to electronic security incidents may include (i) identifying a plurality of security incidents that each occurred within a computing environment and call for a security response, (ii) establishing relationships among the plurality of security incidents by, for each security incident, (a) calculating a feature vector indicating at least one feature of the security incident, (b) using the feature vector to calculate a degree of similarity between the security incident and an additional security and (c) creating an association between the security incident and the additional security incident that reflects the degree of similarity between the security incident and the additional security incident, and (iii) triggering, based on the relationships among the plurality of security incidents, a security action that responds to at least the security incident and the additional security incident.
    Type: Grant
    Filed: September 14, 2016
    Date of Patent: May 7, 2019
    Assignee: Symantec Corporation
    Inventors: Brian Schlatter, Adam Glick, Akshata Krishnamoorthy Rao, Feng Li
  • Patent number: 10273296
    Abstract: Musculoskeletal fibroproliferative disorders, such as Dupuytren's disease may be treated by administering locally a TNF-? antagonist. TNF-? antagonists find particular utility in inhibiting the progression of early disease state Dupuytren's disease and other musculoskeletal fibroproliferative disorders and, in combination with extracellular matrix degradation agents (such as collagenase or matrix metalloproteinase I), treating advanced disease state Dupuytren's disease and, in particular inhibiting recurrence.
    Type: Grant
    Filed: September 11, 2015
    Date of Patent: April 30, 2019
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Jagdeep Nanchahal, Kim Suzanne Midwood
  • Patent number: 10258073
    Abstract: The present invention discloses a functional nutritional blend comprising Gynostemma pentaphyllum extract, Coleus forskohlii extract, Zingiber officinale extract and piperine, for increasing metabolic efficiency and inhibition of adipogenesis.
    Type: Grant
    Filed: May 19, 2017
    Date of Patent: April 16, 2019
    Assignee: SAMI LABS LIMITED
    Inventors: Muhammed Majeed, Kalyanam Nagabhushanam, Mitchell Chavez
  • Patent number: 10246497
    Abstract: The invention relates to PYY compounds having the amino acid in the position corresponding to position 30 of hPYY(1-36) substituted with tryptophan and derivatives thereof with a modifying group attached to the position corresponding to position 7 of hPYY(1-36). The compounds of the invention are selective Y2 receptor agonists. The invention also relates to pharmaceutical compositions comprising such PYY compounds and pharmaceutically acceptable excipients, as well as the medical use of the PYY compounds.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: April 2, 2019
    Assignee: Novo Nordisk A/S
    Inventors: Soeren Oestergaard, Kilian Waldemar Conde Frieboes, Birgit Wieczorek, Jens Kaalby Thomsen, Birgitte Schjellerup Wulff, Carsten Jessen
  • Patent number: 10245304
    Abstract: The invention provides methods of treating ?-galactosidase A deficiency. Dosage forms, methods of administration, and methods of analyzing human ?-galactosidase A are also included.
    Type: Grant
    Filed: November 14, 2016
    Date of Patent: April 2, 2019
    Assignee: SHIRE HUMAN GENETIC THERAPIES, INC.
    Inventors: Douglas A. Treco, Kenneth Loveday, Marianne Borowski
  • Patent number: 10239832
    Abstract: Described herein are compounds of Formula I, methods of making such compounds, pharmaceutical compositions and medicaments containing such compounds, and compounds I for use to treat or prevent diseases or conditions associated with the enzyme glucosylceramide synthase (GCS).
    Type: Grant
    Filed: October 28, 2014
    Date of Patent: March 26, 2019
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventor: Bing Wang
  • Patent number: 10238617
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Grant
    Filed: December 29, 2017
    Date of Patent: March 26, 2019
    Assignee: AXCELLA HEALTH INC.
    Inventors: Michael Hamill, Raffi Afeyan, Chung-Wei Lee, Harry Luithardt, David Berry
  • Patent number: 10203323
    Abstract: Disclosed herein are methods for identifying novel drug candidates.
    Type: Grant
    Filed: August 2, 2016
    Date of Patent: February 12, 2019
    Assignee: Warp Drive Bio, Inc.
    Inventors: Gregory L. Verdine, David W. White, David M. Armistead, Deborah J. Palestrant, Brian Y. Chow, Chris K. Varma, Mathew Edward Sowa
  • Patent number: 10201513
    Abstract: This disclosure provides pharmaceutical compositions comprising amino acid entities and uses thereof. Methods for improving liver function and for treating liver diseases comprising administering an effective amount of the compositions to a subject in need thereof are also disclosed.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: February 12, 2019
    Assignee: AXCELLA HEALTH INC.
    Inventors: Michael Hamill, Raffi Afeyan
  • Patent number: 10172820
    Abstract: The present invention relates to a skin preparation composition for external use having excellent antiseptic ability without using chemical antiseptics. More particularly, the present invention relates to a skin preparation composition for external use, comprising: glyceryl undecylenate having excellent antiseptic ability; and one or more mixtures of ethylhexylglycerin, glyceryl caprylate, p-anisic acid and a citrus mixed extract, thus improving antiseptic ability through the increased effects of antiseptic abilities of those materials.
    Type: Grant
    Filed: November 23, 2012
    Date of Patent: January 8, 2019
    Assignee: Amorepacific Corporation
    Inventors: Il Young Kwack, Yu Na Yun, Tae Hun Park, Jin Sol Kim, Yun Hyeok Jung, Yeon Ju Hong, Kye Ho Shin
  • Patent number: 10154983
    Abstract: Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and/or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: December 18, 2018
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 10154980
    Abstract: This invention is directed to compositions having synergistic combinations of omega-3 fatty acid such as OMEGA-3 with a tomato extract lycopene, and optionally with carnosic acid and/or lutein. More specifically, the present invention provides compositions having synergistic combinations of the aforementioned compounds, which may be used, inter alia, to inhibit/suppress inflammation via the suppression of the expression of anti-inflammatory mediators or via the suppression of the secretion of anti-inflammatory mediators from macrophages at a site of inflammation.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: December 18, 2018
    Assignee: LYCORED LTD.
    Inventors: Rachel Levy, Nurit Hadad, Tanya Sedlov, Morris Zelkha, Masha Sapojnik
  • Patent number: 10154977
    Abstract: Described herein are compositions and methods relating to particles comprising at least one component of a cellular-derived microparticle. Aspects of technology described herein relate to compositions and methods for treating inflammation, wounds, and pain.
    Type: Grant
    Filed: March 23, 2012
    Date of Patent: December 18, 2018
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventors: Charles N. Serhan, Lucy V. Norling, Matthew Spite, Jesmond P. Dalli
  • Patent number: 10105312
    Abstract: A hair growth oil composition to be applied topically to the human scalp in order to encourage hair growth. The present invention accomplishes these goals through a mixture of ingredients precisely proportioned to achieve a unique chemical composition that brings about maximum results. The ingredients in the composition include coconut oil, emu oil, bhringaraj (eclipta alba), amalaki (emblica officinalis), vitamin E, and pharmaceutically acceptable excipients are described. A method of use is also disclosed.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: October 23, 2018
    Inventor: Keisha Lett
  • Patent number: 10087431
    Abstract: Provided herein are methods of using a Cas1 polypeptide to generate nucleic fragments from a DNA substrate. These methods may be performed in vitro or in vivo. Also provided are methods of screening for modulators of Cas1.
    Type: Grant
    Filed: March 2, 2011
    Date of Patent: October 2, 2018
    Assignee: The Regents of the University of California
    Inventors: Blake Wiedenheft, Kaihong Zhou, Jennifer A. Doudna
  • Patent number: 10080374
    Abstract: The present invention relates to a process for producing cheese, comprising the steps of: providing a first raw material liquid; providing a second raw material liquid; treating the first raw material liquid with a protein crosslinking enzyme to provide an enzyme-treated raw material liquid; mixing the enzyme-treated raw material liquid with the second raw material liquid to provide cheese milk; processing the cheese milk into cheese. The process produces cheese in improved yields while retaining the organoleptic properties of cheese unchanged. The invention further relates to cheese treated with a protein crosslinking enzyme, having the moisture on a fat-free basis of 67% or less and a protein profile of cheese has proteins of molecular weight of less than 66 kDa.
    Type: Grant
    Filed: June 14, 2012
    Date of Patent: September 25, 2018
    Assignee: VALIO LTD.
    Inventors: Terhi Aaltonen, Päivi Myllärinen, Ilkka Huumonen, Emmi Martikainen
  • Patent number: 10071030
    Abstract: The present invention relates to a carrier for the delivery of a nutraceutical or cosmeceutical active comprising non-neutralized tocopheryl phosphate and a hydrophobic vehicle. The present invention also relates to a formulation comprising the carrier and a nutraceutical or cosmeceutical active.
    Type: Grant
    Filed: February 4, 2011
    Date of Patent: September 11, 2018
    Assignee: Phosphagenics Limited
    Inventor: Roksan Libinaki
  • Patent number: 10058612
    Abstract: Some aspects of the invention provide for a method of treating Impaired Energy Processing Disorders and Mitochondrial Deficiencies using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: August 28, 2018
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 10058522
    Abstract: Some aspects of the invention provide for a method of treating Wet and/or Dry Age-related Macular Degeneration, Retinitis Pigmentosa, Diabetic Retinopathy, cataracts, and/or Stargardt Disease using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and/or suppress the rate of formation of reactive products and toxic compounds.
    Type: Grant
    Filed: April 24, 2012
    Date of Patent: August 28, 2018
    Assignee: Retrotope, Inc.
    Inventor: Mikhail S. Shchepinov
  • Patent number: 10046034
    Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: August 14, 2018
    Assignee: BIOM'UP
    Inventors: Christian Gagnieu, Patricia Forest, Sylvain Picot
  • Patent number: 10039812
    Abstract: The invention relates to deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a pharmaceutical or veterinary composition or formulation comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a combination therapeutic comprising at least deoxyribonuclease for use in the treatment of a suspected or existing C. difficile infection; a method of treating a mammal suspected of being infected with, or infected with, C. difficile comprising the use of at least deoxyribonuclease; a method of cleaning or sterilizing a material or product comprising the use of at least deoxyribonuclease; and a cleaning or sterilizing product impregnated with or containing at least deoxyribonuclease.
    Type: Grant
    Filed: November 4, 2015
    Date of Patent: August 7, 2018
    Assignee: London School of Hygiene and Tropical Medicine
    Inventors: Lisa Dawson, Brendan Wren
  • Patent number: 10035985
    Abstract: This invention relates to adeno-associated viral (AVV) vectors, to producer cell lines for the production of AAV vectors and to methods of producing such vectors. More specifically, the invention relates to producer cell lines adapted to increase the titer of said vectors and methods of producing AAV vectors using said producer cell lines.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: July 31, 2018
    Inventors: Yuan Zhao, Stifani Satkunanathan
  • Patent number: 10028914
    Abstract: The present invention describes a reduction type coenzyme Q10 powder, a composition thereof, and a preparation method thereof. The reduction type coenzyme Q10 powder is obtained by reacting an oxidation type coenzyme Q10 with the presence of a reducing agent, removing an organic solvent and other purities from a reaction solution after the reaction is finished to obtain an oil-soluble reduction type coenzyme Q10 liquid, and then directly performing prill formation with cold wind on an obtained reduction type coenzyme Q10 greasy substance. The obtained reduction type coenzyme Q10 powder has a lower crystallinity, and in a Cu-K[alpha] X-ray diffraction spectrum, has a strong peak at a diffraction angle 2[theta] being 18.9 DEG, and has a very strong absorption peak at a diffraction angle 2[theta] being 22.8 DEG.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: July 24, 2018
    Assignee: ZHEJIANG MEDICINE CO., LTD. XINCHANG PHARMACEUTICA FACTORY
    Inventors: Xinde Xu, Gang Chen, Xuejun Lao, Lihua Zhang, Xiaoxia Sun, Xiaoyue Jiang
  • Patent number: 10024846
    Abstract: The invention provides a method for treating or preventing diet-induced obesity in a subject comprising administering an agent in an effective amount so that expression or activity of the P2Y2 receptor is decreased or inhibited in the subject thereby treating or preventing diet-induced obesity in the subject.
    Type: Grant
    Filed: April 27, 2015
    Date of Patent: July 17, 2018
    Assignee: The United States of America as represented by the Department of Veterans Affairs
    Inventors: Bellamkonda K. Kishore, Yue Zhang, Carolyn M. Ecelbarger
  • Patent number: 9994828
    Abstract: This disclosure concerns recombinant host organisms genetically modified with a polyunsaturated fatty acid (PUFA) synthase system and one or more accessory proteins that allow for and/or improve the production of PUFAs in the host organism. The disclosure also concerns methods of making and using such organisms as well as products obtained from such organisms.
    Type: Grant
    Filed: November 26, 2014
    Date of Patent: June 12, 2018
    Assignees: Dow AgroSciences LLC, DSM IP Assets B.V.
    Inventors: Terence A. Walsh, Daniel J. Gachotte, Cory M. Larsen, Scott Bevan, P. Ann Owens-Merlo, James G. Metz, Ross Zirkle
  • Patent number: 9994831
    Abstract: The present disclosure provides compositions and methods for binding and/or cleaving a single stranded target nucleic acid. Subject compositions include a Cas9 polypeptide, a guide nucleic acid, and a PAMmer. A subject PAMmer is a single stranded oligonucleotide having a protospacer adjacent motif (PAM) sequence and at least one of: a specifity segment positioned 5? of the PAM sequence, and an orientation segment positioned 3? of the PAM sequence. In some embodiments, the Cas9 polypeptide is a variant Cas9 polypeptide having reduced nuclease activity relative to a corresponding wild type Cas9 polypeptide. In some cases, methods of binding are for visualizing single stranded target nucleic acids using a detectable label. In some cases, methods of binding are for isolating, collecting, and/or analyzing at least one of: (i) bound single stranded target nucleic acids; and (ii) polypeptides associated with bound single stranded target nucleic acids.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 12, 2018
    Assignee: The Regents of the University of California
    Inventors: Jennifer A. Doudna, Samuel H. Sternberg, Mitchell O'Connell, Benjamin Oakes
  • Patent number: 9956179
    Abstract: This invention discloses a process for making nanoparticles of amphiphilic copolymers by flash precipitation. Nanoparticles may be of amphiphilic copolymer alone or may contain an additive target molecule, preferably an organic active. The inclusion of additive target molecules in amphiphilic copolymer nanoparticles can alter their water solubility characteristics, fluid dynamics, and/or stability. Changing an additive target molecule's solubility and stability in a nanoparticle can make a water insoluble compound suitable for pharmaceutical administration as well as specifically target the molecule to a specific area of a patient's body. The process affords the production of nanoparticles at high absolute active content, at high yield, high productivity, and high processing rates while using unusually low amounts of amphiphilic copolymers. Furthermore, the resulting particles exhibit sufficient stability for post processing as desired.
    Type: Grant
    Filed: February 8, 2012
    Date of Patent: May 1, 2018
    Assignee: The Trustees of Princeton University
    Inventors: Brian K. Johnson, Robert K. Prud'homme
  • Patent number: 9957546
    Abstract: The present invention is directed to a phospholipid-based NIR molecular beacon, having a phospholipid moiety; with an NIR fluorophore moiety covalently linked to a phospholipid glycerol backbone and a quencher moiety covalently linked to the phospholipid glycerol backbone. Additionally, provided herein is methods of analyzing a sample for the presence of a phospholipase and methods of identifying the activity of a phospholipase in vivo utilizing phospholipid-based NIR molecular beacon.
    Type: Grant
    Filed: March 3, 2009
    Date of Patent: May 1, 2018
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: E. J. Delikatny, Anatoliy V. Popov, Gang Zheng, Theresa Mawn
  • Patent number: 9950023
    Abstract: An all-natural composition for treating acne, the composition comprising: N-acetylcysteine (NAC); Nicotinamide; Resveratrol; Rhodionin; Epigallocatechin gallate (EGCG); Vitamin A; Vitamin E; Vitamin D3, Allicin; and Propolis.
    Type: Grant
    Filed: November 21, 2014
    Date of Patent: April 24, 2018
    Inventor: Parham Michael Tabibian
  • Patent number: 9938242
    Abstract: A method for producing a compound (3), which comprises allowing a compound (1) to react with hydrogen gas in an inert solvent, in the presence of a specific chiral ligand and a ruthenium catalyst, or in the presence of an asymmetric transition metal complex catalyst previously generated from the chiral ligand and the ruthenium catalyst.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: April 10, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Tsuyoshi Ueda, Kazutoshi Ukai